Results 11 to 20 of about 12,392,515 (266)
Nine areas with outstanding challenges for hemophilia B research [PDF]
Therapeutic Advances in HematologyHemophilia A and B are rare, X-linked bleeding disorders characterized by deficiencies in coagulation factor VIII (FVIII) and factor IX (FIX), respectively. Numerous advances have helped to reduce disease burden.
Jan Astermark +4 more
doaj +4 more sources
Managing Relevant Clinical Conditions of Hemophilia A/B Patients [PDF]
Hematology Reports, 2023 The Medical Directors of nine Italian Hemophilia Centers reviewed and discussed the key issues concerning the replacement therapy of hemophilia patients during a one-day consensus conference held in Rome one year ago. Particular attention was paid to the
Massimo Morfini +9 more
doaj +2 more sources
Clinical, instrumental, serological and histological findings suggest that hemophilia B may be less severe than hemophilia A [PDF]
Haematologica, 2016 Recent evidence suggests that patients with severe hemophilia B may have a less severe disease compared to severe hemophilia A. To investigate clinical, radiological, laboratory and histological differences in the arthropathy of severe hemophilia A and ...
Daniela Melchiorre +9 more
doaj +2 more sources
Cardiac surgery in an infant hemophilia B carrier with moderate hemophilia: a case report [PDF]
Frontiers in Cardiovascular MedicineIntroductionThis is the first reported case of a female infant with moderate hemophilia B undergoing complex cardiac surgery, highlighting challenges in managing bleeding disorders in this rare clinical setting.Patient concerns and clinical findingsA 4 ...
Julia Hölz +5 more
doaj +2 more sources
The bleeding disorder known as hemophilia B (HB) is caused by a deficiency or abnormality in the blood clotting factor IX (FIX) gene, which is inherited in an X-linked manner. This disease results from one of more than 1000 classified pathogenic variations in the FIX gene F9, and genetic missense and frameshift changes predominate.
Killeen RB, Rokkam VR.
europepmc +3 more sources
A Case of Hemophilia B with Abdominal and Pelvic Pseudotumor
罕见病研究, 2022 Hemophilia B is a genetic disorder caused by coagulation factor Ⅸ(FⅨ) deficiency, mainly manifesting as joint, muscle and deep tissue bleeding. Hemophilia pseudotumor is a mass formed by soft tissue liquefaction and necrosis caused by repeated bleeding ...
ZHANG Jing +7 more
doaj +2 more sources
Cochlear implantation in hemophilia B—a rare case report
The Egyptian Journal of Otolaryngology, 2022 Background Hemophilia B is an X-linked inherited disease, mainly caused by deficiency of factor IX. Severity of the disease is manifested by the factor IX deficiency in the blood.
Chetan Yadav +3 more
doaj +2 more sources
BMC Health Services Research, 2022 Background Hemophilia care in mainland China has been greatly improved since the establishment of the Hemophilia Treatment Center Collaborative Network of China (HTCCNC), and most of drugs for hemophilia have been covered by basic medical insurance ...
Zhengwei Huang +6 more
doaj +1 more source
A Case of Acquired Hemophilia A and Congenital Hemophilia B
Cureus, 2022 Congenital hemophilia B is a rare, inherited X-linked bleeding disorder caused by a deficiency of factor IX (FIX). Acquired hemophilia A is a rare, acquired bleeding disorder which presents as new onset bleeding in older adults due to the development of autoantibodies against factor VIII (FVIII).
Fortier, Julia C +4 more
openaire +2 more sources
Adeno‐associated virus serotype 2 capsid variants for improved liver‐directed gene therapy
Hepatology, EarlyView., 2022 Abstract Background and Aims Current liver‐directed gene therapies look for adeno‐associated virus (AAV) vectors with improved efficacy. With this background, capsid engineering is explored. Whereas shuffled capsid library screenings have resulted in potent liver targeting variants with one first vector in human clinical trials, modifying natural ...
Nadja Meumann +25 more
wiley +1 more source